A combinatorial strategy for treating KRAS-mutant lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• KRAS-mutant lung adenocarcinoma is a significant challenge in cancer therapy.
• Directly inhibiting KRAS is difficult, and targeting its effectors often leads to resistance via compensatory pathways.

Purpose of the Study:

• To identify combination targets for trametinib, a MEK inhibitor, to overcome resistance in KRAS-mutant lung cancer.
• To investigate the compensatory mechanisms activated by trametinib treatment.

Main Methods:

• Utilized a short-hairpin RNA screen to identify resistance pathways.
• Investigated the role of fibroblast growth factor receptor 1 (FGFR1) in trametinib resistance.
• Evaluated the efficacy of combining trametinib with FGFR1 inhibition in vitro and in vivo models.

Main Results:

• Trametinib treatment induces a compensatory FGFR1 response, leading to signaling rebound and adaptive resistance.
• Combined inhibition of FGFR1 and trametinib significantly enhances tumor cell death.
• FGFR1-mediated resistance is specific to KRAS-mutant lung and pancreatic cancers.

Conclusions:

• FGFR1 plays a critical role in mediating adaptive resistance to trametinib in KRAS-mutant lung cancer.
• Combining trametinib with FGFR1 inhibitors represents a promising therapeutic strategy for this patient population.